Jump to content

Rigerimod

Edit links
From Wikipedia, the free encyclopedia

This is the current revision of this page, as edited by Citation bot (talk | contribs) at 09:38, 21 August 2022 (Alter: title. | Use this bot. Report bugs. | Suggested by BrownHairedGirl | #UCB_webform 3558/3834). The present address (URL) is a permanent link to this version.

(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)

Rigerimod (IPP-201101, Lupuzor) is a polypeptide corresponding to the sequence 131-151 of the 70k snRNP protein with a serine phosphorylated in position 140.[1]

It gave encouraging results in a phase IIb trial for severe lupus.[1] Another phase IIb trial has started recruiting in the US.[2]

References

[edit]
  1. ^ a b http://www.medicalnewstoday.com/articles/171853.php 23 Nov 2009
  2. ^ "Cephalon, ImmuPharma license partner for Rigerimod (Lupuzor) initiates critical steps in its development program". Archived from the original on 2011-09-10. Retrieved 2010-06-28.


Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Rigerimod&oldid=1105696335"